Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHOK PATEL

NPI
1093809576
CMS profile
276954
Location
TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,969.84

33 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHOK PATEL

NPI 1093809576 · CMS profile ID 276954

TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1093809576?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

33 matching records · $2,969.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 33 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–33 of 33.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $11.0112/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297449 CMS
Allergan, Inc. $13.7912/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297447 CMS
Eisai Inc. $11.7511/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751251443 CMS
Avanir Pharmaceuticals, Inc. $13.5311/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722217817 CMS
Allergan, Inc. $3.5411/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297445 CMS
Allergan, Inc. $13.9911/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297441 CMS
Allergan, Inc. $14.3511/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297443 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0510/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747278815 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.4610/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747278813 CMS
Allergan, Inc. $6.9910/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297439 CMS
Eisai Inc. $11.2010/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751232851 CMS
Allergan, Inc. $14.7409/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297437 CMS
Allergan, Inc. $3.2509/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297435 CMS
Otsuka America Pharmaceutical, Inc. $13.5209/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748770079 CMS
Allergan, Inc. $11.0409/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297433 CMS
Allergan, Inc. $1,320.0009/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297431 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7409/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747278811 CMS
Allergan, Inc. $13.6108/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297429 CMS
Merck Sharp & Dohme Corporation $13.9708/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747688207 CMS
Allergan, Inc. $12.5908/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297427 CMS
Otsuka America Pharmaceutical, Inc. $13.5208/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748770075 CMS
Allergan, Inc. $13.1208/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297425 CMS
Allergan, Inc. $10.5807/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297423 CMS
Allergan, Inc. $9.4807/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297421 CMS
Allergan, Inc. $7.8706/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297419 CMS
Allergan, Inc. $14.1204/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297417 CMS
Allergan, Inc. $13.9903/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297415 CMS
Jazz Pharmaceuticals Inc. $14.0902/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745453123 CMS
Allergan, Inc. $1.3902/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297413 CMS
Allergan, Inc. $1,300.0002/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297411 CMS
Allergan, Inc. $1.2501/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297409 CMS
Allergan, Inc. $12.3201/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723297407 CMS
Teva Pharmaceuticals USA, Inc. $12.9901/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749467415 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.42 66
PY2020 $2,969.84 33
PY2021 $7,553.27 35
PY2022 $6,054.38 18
PY2023 $14,560.76 55
PY2024 $22,723.92 31
PY2025 $6,910.62 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,752.51 11
PY2025 Principal investigator $1,229,009.00 130
PY2024 Principal investigator $3,194,861.98 28
PY2023 Recipient $355.00 1
PY2023 Principal investigator $1,914,939.19 59
PY2022 Recipient $1,248.00 4
PY2022 Principal investigator $1,105,512.02 75
PY2021 Recipient $13,374.00 3
PY2021 Principal investigator $1,695,784.21 81
PY2020 Recipient $6,288.97 21
PY2020 Principal investigator $1,118,610.73 104
PY2019 Recipient $18,854.85 12
PY2019 Principal investigator $1,138,230.38 171

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

125 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $5,642.16 12/31/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330419
Principal investigator 1 Allergan, Inc. $250.00 12/31/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330421
Principal investigator 1 Allergan, Inc. $2,951.36 12/31/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330423
Principal investigator 1 Allergan, Inc. $694.50 12/31/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330425
Principal investigator 1 Allergan, Inc. $3,436.23 12/31/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330427
Principal investigator 1 Amgen Inc. $907.86 12/28/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 753889395
Principal investigator 1 Eli Lilly and Company $18,400.00 12/28/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 728731991
Principal investigator 1 Allergan, Inc. $24,602.15 12/23/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330417
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,532.81 12/21/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 748385291
Principal investigator 1 Eisai Inc. $12,951.00 12/21/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102483
Principal investigator 1 Allergan, Inc. $5,334.25 12/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330413
Principal investigator 1 Allergan, Inc. $1,476.30 12/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330415
Principal investigator 1 Allergan, Inc. $552.00 12/08/2020 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330411
Principal investigator 1 Eisai Inc. $19,872.00 12/08/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102465
Principal investigator 1 Eisai Inc. $5,312.18 12/08/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102467
Principal investigator 1 Eisai Inc. $2,570.79 12/08/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102471
Principal investigator 1 ITI, Inc. $12,487.40 12/04/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) No dispute reported 06/30/2026 750026701
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $16,451.50 12/03/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A randomized, double-blind, placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 748986373
Principal investigator 1 Allergan, Inc. $5,602.15 11/23/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330409
Principal investigator 1 ACADIA Pharmaceuticals Inc $10,282.23 11/20/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 748385139
Principal investigator 1 Allergan, Inc. $9,533.25 11/19/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330407
Principal investigator 1 Allergan, Inc. $1,886.70 11/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330405
Principal investigator 1 Amgen Inc. $1,210.48 11/09/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 753889379
Principal investigator 1 Eli Lilly and Company $646.19 11/09/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 728732507
Principal investigator 1 Allergan, Inc. $29,412.00 10/23/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330403
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,901.12 10/20/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 748384999
Principal investigator 1 Allergan, Inc. $327.00 10/20/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721304289
Principal investigator 1 Allergan, Inc. $2,500.00 10/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330397
Principal investigator 1 Allergan, Inc. $2,500.00 10/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330399
Principal investigator 1 Allergan, Inc. $10,000.00 10/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330401
Principal investigator 1 Eisai Inc. $35,233.20 10/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102489
Principal investigator 1 Allergan, Inc. $1,928.50 10/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330395
Recipient Eli Lilly and Company $50.00 09/30/2020 Covered Recipient Physician A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 728716461
Principal investigator 1 Eisai Inc. $20,157.00 09/21/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102493
Principal investigator 1 Allergan, Inc. $3,505.50 09/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330393
Principal investigator 1 Allergan, Inc. $700.00 09/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721296423
Principal investigator 1 Allergan, Inc. $4,761.20 09/07/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330391
Recipient Eli Lilly and Company $100.00 08/31/2020 Covered Recipient Physician A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK No dispute reported 06/30/2026 728717747
Principal investigator 1 Allergan, Inc. $1,170.30 08/24/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330389
Principal investigator 1 Allergan, Inc. $276.00 08/21/2020 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330387
Principal investigator 1 Eisai Inc. $7,901.10 08/19/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102487
Principal investigator 1 Allergan, Inc. $6,481.85 08/13/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330385
Recipient Eli Lilly and Company $130.00 08/10/2020 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 728717151
Recipient Eli Lilly and Company $76.50 08/10/2020 Covered Recipient Physician A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 728717517
Principal investigator 1 Allergan, Inc. $6,565.45 08/07/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330383
Principal investigator 1 Eisai Inc. $1,321.20 08/05/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102469
Principal investigator 1 Allergan, Inc. $86.00 07/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721287755
Principal investigator 1 Allergan, Inc. $700.00 07/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721287341
Principal investigator 1 Eisai Inc. $8,796.60 07/20/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102463
Principal investigator 1 Eisai Inc. $2,985.00 07/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749101951
Principal investigator 1 Eisai Inc. $2,985.00 07/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749101953
Principal investigator 1 Eisai Inc. $2,985.00 07/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749101955
Principal investigator 1 Eisai Inc. $25,720.40 07/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102313
Principal investigator 1 Eisai Inc. $245.10 07/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102319
Principal investigator 1 Allergan, Inc. $7,501.15 07/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330381
Principal investigator 1 Eisai Inc. $3,000.00 07/09/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749102485
Principal investigator 1 Allergan, Inc. $5,775.05 06/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330379
Principal investigator 1 Allergan, Inc. $2,362.65 05/20/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330377
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $2,529.30 05/20/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A 12-WEEK, MULTICENTER, ACTIVE-TREATMENT EXTENSION TRIAL TO EVAULATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMER'S TYPE No dispute reported 06/30/2026 748804803
Principal investigator 1 Allergan, Inc. $1,360.40 05/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330375
Principal investigator 1 Allergan, Inc. $4,881.10 05/13/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330373
Principal investigator 1 Allergan, Inc. $660.00 05/12/2020 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330371
Principal investigator 1 Eisai Inc. $691.20 05/12/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 749101941
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,443.08 05/05/2020 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 748383087
Principal investigator 1 Avanir Pharmaceuticals, Inc. $10,382.55 04/29/2020 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 722220611
Principal investigator 1 Allergan, Inc. $5,857.70 04/17/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330369
Principal investigator 1 Allergan, Inc. $4,989.40 04/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330365
Principal investigator 1 Allergan, Inc. $3,108.40 04/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330367
Recipient Eli Lilly and Company $4,193.00 04/07/2020 Covered Recipient Physician EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY No dispute reported 06/30/2026 728717515
Principal investigator 1 ACADIA Pharmaceuticals Inc $17,677.40 04/06/2020 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-045 No dispute reported 06/30/2026 748382277
Principal investigator 1 Amgen Inc. $17,009.30 03/20/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 731645917
Principal investigator 1 Allergan, Inc. $6,844.75 03/19/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330363
Principal investigator 1 Allergan, Inc. $9,059.20 03/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330361
Principal investigator 1 ACADIA Pharmaceuticals Inc $19,424.10 03/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-048 No dispute reported 06/30/2026 748381775
Principal investigator 1 Allergan, Inc. $5,568.90 03/13/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330359
Principal investigator 1 Allergan, Inc. $327.00 03/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721263525
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $32,310.51 03/11/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 748804141
Principal investigator 1 Allergan, Inc. $6,052.00 03/01/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330357
Principal investigator 1 ACADIA Pharmaceuticals Inc $10,500.00 02/25/2020 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 748381559
Principal investigator 1 Allergan, Inc. $7,776.70 02/24/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330353
Principal investigator 1 Allergan, Inc. $11,502.60 02/24/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330355
Principal investigator 1 Amgen Inc. $14,891.30 02/22/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 731645927
Principal investigator 1 Allergan, Inc. $11,151.10 02/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330351
Principal investigator 1 Allergan, Inc. $2,236.30 02/13/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330349
Principal investigator 1 Amgen Inc. $97.97 02/10/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 731645935
Principal investigator 1 ACADIA Pharmaceuticals Inc $170.00 02/06/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
ACP-103-056 No dispute reported 06/30/2026 748381385
Principal investigator 1 Amgen Inc. $13,341.00 01/30/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 731645931
Principal investigator 1 Avanir Pharmaceuticals, Inc. $4,000.00 01/29/2020 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
17-AVP-786-305 No dispute reported 06/30/2026 722219423
Principal investigator 1 Allergan, Inc. $385.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721252339
Principal investigator 1 Allergan, Inc. $225.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD). No dispute reported 06/30/2026 721253539
Recipient ACADIA Pharmaceuticals Inc $104.65 01/26/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379921
Recipient ACADIA Pharmaceuticals Inc $19.50 01/25/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379907
Recipient ACADIA Pharmaceuticals Inc $43.21 01/25/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379911
Recipient ACADIA Pharmaceuticals Inc $7.39 01/25/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379915
Recipient ACADIA Pharmaceuticals Inc $38.65 01/25/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379917
Recipient ACADIA Pharmaceuticals Inc $63.15 01/24/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379889
Recipient ACADIA Pharmaceuticals Inc $41.89 01/24/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379893
Recipient ACADIA Pharmaceuticals Inc $50.86 01/24/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379895
Recipient ACADIA Pharmaceuticals Inc $20.39 01/24/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379899
Recipient ACADIA Pharmaceuticals Inc $75.56 01/24/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379901
Recipient ACADIA Pharmaceuticals Inc $17.44 01/24/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379905
Recipient ACADIA Pharmaceuticals Inc $49.00 01/23/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379875
Recipient ACADIA Pharmaceuticals Inc $63.40 01/23/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379879
Recipient ACADIA Pharmaceuticals Inc $542.26 01/23/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379883
Recipient ACADIA Pharmaceuticals Inc $172.33 01/23/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379885
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,198.50 01/23/2020 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-303 No dispute reported 06/30/2026 722219421
Principal investigator 1 Allergan, Inc. $4,290.20 01/22/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330345
Principal investigator 1 Allergan, Inc. $11,867.40 01/22/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330347
Principal investigator 1 Genentech, Inc. $17,735.50 01/21/2020 Non-covered Recipient Entity
BIO BEHAVIORHAL HEALTH
GTP1 PHASE I LONGITUDINAL STUDY No dispute reported 06/30/2026 743035619
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $222,757.30 01/21/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 748803579
Principal investigator 1 ACADIA Pharmaceuticals Inc $3,237.89 01/20/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
ACP-103-056 No dispute reported 06/30/2026 748381097
Principal investigator 1 Eli Lilly and Company $4,257.50 01/16/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728732509
Principal investigator 1 Allergan, Inc. $3,086.55 01/15/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721330343
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721246763
Principal investigator 1 Allergan, Inc. $2,000.00 01/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330339
Principal investigator 1 Allergan, Inc. $12,200.85 01/14/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330341
Principal investigator 1 Eli Lilly and Company $3,801.90 01/09/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY No dispute reported 06/30/2026 728731161
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $101,724.71 01/09/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 748802889
Recipient ACADIA Pharmaceuticals Inc $429.79 01/07/2020 Covered Recipient Physician ACP-103-063 No dispute reported 06/30/2026 748379873
Principal investigator 1 Eli Lilly and Company $119,542.59 01/07/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY No dispute reported 06/30/2026 728731101
Principal investigator 1 Allergan, Inc. $737.53 01/03/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330337
Principal investigator 1 Amgen Inc. $16,817.28 01/03/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 731645923
Principal investigator 1 Allergan, Inc. $113.93 01/01/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330331
Principal investigator 1 Allergan, Inc. $126.55 01/01/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330333
Principal investigator 1 Allergan, Inc. $206.43 01/01/2020 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721330335